Erciyes University (ERÜ) has initiated the administration of the first dose within the Phase 2 trials of the novel coronavirus (COVID-19) vaccine candidate. Within this scope, the first dose of the inactivated vaccine candidate, which began Phase 1 trials on November 5, 2020, has started to be administered to volunteers as part of the Phase 2 study.
At the Erciyes University Vaccine Research and Development Application and Research Center (ERAGEM), the first dose in the Phase 2 trials of the inactivated vaccine candidate—developed against COVID-19 and supported by the Ministry of Health and the Turkey Health Institutes Presidency (TÜSEB)—was administered to a volunteer at the Erciyes University Good Clinical Practice and Research Center (İKUM).
